The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia, MD, PhD, University of Insubria, Varese, Italy, discusses the final analysis of a European Research Initiative on CLL (ERIC) study that investigated autoimmune cytopenias in patients with chronic lymphocytic leukemia (CLL) receiving venetoclax-based therapy, highlighting that these treatments benefited patients with pre-existing autoimmune cytopenias. Prof. Coscia also notes that treatment-emergent autoimmune cytopenias were less common than in patients receiving venetoclax monotherapy, and that these events are easily managed with standard treatments. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
